Drug Information

Drug General Information
Drug ID
D0L3DK
Former ID
DAP001544
Drug Name
Vildagliptin
Synonyms
Equa; Galvu; Galvus; Jalra; Xiliarx; LAF 237; LAF237; Galvus (TN); LAF-237; NVP-LAF 237; NVP-LAF237; Vidagliptin (see Vildagliptin); NVP-LAF-237; Vildagliptin (JAN/USAN/INN); (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI)
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Approved [537022], [541460]
Company
Novartis
Structure
Download
2D MOL

3D MOL
Formula
C17H25N3O2
InChI
InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
InChIKey
SYOKIDBDQMKNDQ-XWTIBIIYSA-N
CAS Number
CAS 274901-16-5
PubChem Compound ID
6918537
PubChem Substance ID
12015446, 14849686, 14898545, 17194948, 43529907, 46512217, 50459774, 51091422, 57371966, 99443227, 103381660, 104178744, 114788130, 118314324, 121147405, 124772155, 126651432, 129307316, 134358368, 135683855, 136375110, 137004291, 139563570, 152037539, 152159633, 160967824, 172085080, 172914664, 174477837, 175266579, 175426398, 178102929, 186021611, 196105655, 210275077, 210280715, 224646668, 226406746, 249810559, 251883214, 252032033, 252160316, 252216578, 252308983
SuperDrug ATC ID
A10BH02
Target and Pathway
Target(s) Dipeptidyl peptidase IV Target Info Inhibitor [537022]
KEGG Pathway Protein digestion and absorption
NetPath Pathway IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
References
Ref 537022Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
Ref 541460(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6310).
Ref 537022Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.